---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004989"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:52:05.286421+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "low"
source: SEC EDGAR
---

# Jazz Pharma confirms FY2024 revenue guidance met at J.P. Morgan conference

## Summary
- Company expects to meet previously announced total, neuroscience and oncology revenue guidance for year ended Dec 31, 2024.
- Outlook disclosed at J.P. Morgan Healthcare Conference on Jan 14, 2025.
- No specific revenue or EPS figures provided; guidance ranges unchanged.

## SEC filing metadata
- accession: 0001193125-25-004989
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312525004989/0001193125-25-004989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312525004989/d699726d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004989
- JSON: https://secwatch.observer/filing/0001193125-25-004989.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004989.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.